|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Center for Complementary and Alternative Medicine (NCCAM) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Information provided by: | National Center for Complementary and Alternative Medicine (NCCAM) |
| ClinicalTrials.gov Identifier: | NCT00065403 |
Purpose
Little is known about acupuncture's efficacy for Irritable Bowel Syndrome (IBS). This trial uses a manualized acupuncture treatment format that closely follows clinical practice and allows flexibility in designing individualized treatments. In addition, a second parallel qualitative study will follow a subgroup of patients throughout the trial to explore the relationships between patients' interpretations and understandings (what anthropologists call "meaning") of irritable bowel and their response to treatment. Cortisol levels (an important stress hormone) will also be assessed.
This will be a 3-arm trial: Active acupuncture, placebo acupuncture, and wait list.
| Condition | Intervention | Phase |
|
Irritable Bowel Syndrome |
Device: Acupuncture |
Phase I Phase II |
| MedlinePlus related topics: | Acupuncture |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Eligibility
| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Diagnosis of Irritable Bowel Syndrome based on Rome II criteria, including at least 12 weeks of abdominal discomfort or pain in the last 12 months with at least 2 of the following features:
Exclusion criteria:
Contacts and Locations| United States, Massachusetts | |||||
| Harvard Medical School | |||||
| Boston, Massachusetts, United States, 02115 | |||||
| National Center for Complementary and Alternative Medicine (NCCAM) |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Principal Investigator: | Ted Kaptchuk, OMD | Harvard University |
More Information
| Study ID Numbers: | R01 AT001414, KaptchukTJ |
| First Received: | July 22, 2003 |
| Last Updated: | August 16, 2006 |
| ClinicalTrials.gov Identifier: | NCT00065403 |
| Health Authority: | United States: Federal Government |
|
|
|
|